Infection-Associated Mortality During Induction Chemotherapy in Group B Intermediate-Risk Pediatric Burkitt's Lymphoma

被引:0
|
作者
Jaffari, Syed Muhammad Ibne Ali [1 ]
Hashmi, Masooma [2 ]
Hashmi, Abdul Wasey [1 ]
Nisar, Samaha [1 ]
Ashraf, Hafsa [1 ]
Tariq, Ghufran [3 ]
Farooq, Arslan [4 ]
Awan, Javeria [5 ]
Zaidi, Wasey Syed Muhammad Jawad [6 ,7 ]
Kaneez, Mehwish [6 ,7 ]
机构
[1] Shalamar Med & Dent Coll, Pediat, Lahore, Pakistan
[2] Royal Wolverhampton NHS Trust, Walsall Manor Hosp, Internal Med, Walsall, England
[3] Arif Mem Teaching Hosp, Pediat, Lahore, Pakistan
[4] Combined Mil Hosp, Internal Med, Lahore, Pakistan
[5] Rawalpindi Med Univ, Pediat, Rawalpindi, Pakistan
[6] Holy Family Hosp, Pediat, Rawalpindi, Pakistan
[7] Shaukat Khanum Mem Canc Hosp & Res Ctr, Pediat Oncol, Lahore, Pakistan
关键词
Categories; Pediatrics; Disease; Oncology bacterial infections; induction chemotherapy; infection-associated mortality; intermediate risk; burkitt's lymphoma; MIDDLE-INCOME COUNTRIES; CHILDHOOD-CANCER; CHILDREN; EXPERIENCE; MANAGEMENT;
D O I
10.7759/cureus.40365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Burkitt's lymphoma (BL) in the pediatric population has significant burden in developing countries. Infection-related complications during the induction chemotherapy phase pose a major challenge and contribute to high mortality rates due to a severely immunocompromised state. However, there is scarce data on the etiologies and optimal management strategies for infection-related mortality in pediatric BL patients, especially in developing countries like Pakistan.Methods This is a cross-sectional study that included a total of 116 pediatric patients with intermediate-risk BL. All patients were treated based on the Children's Cancer and Leukaemia Group (CCLG) 2020 guidelines. Data on patient demographics, presenting symptoms, diagnosis, infectious etiologies, and outcomes were collected. Infection-related complications and mortality were monitored during the induction chemotherapy period. The results of relevant culture reports were tabulated and data were analyzed.Results Among the 116 included patients, 61.1% were males with a mean age of 4.83 & PLUSMN; 2.12 years. Abdominal BL was the most common anatomical location. During the induction period, 66 patients (56.9%) had culture-proven infections, resulting in 33 deaths (28.4%). Fever was the predominant presenting symptom in all patients, followed by vomiting (57.6%), loose stools (42.4%), and cough (18.2%). Neutropenic colitis, sepsis, pneumonia, and meningitis were among the diagnosed infections. Hospital-acquired bacterial infections, including multi-drug resistant gram-negative and gram-positive organisms, were the main cause of mortality, with fungal infections and cytomegalovirus viremia also identified in a few patients. Conclusions This study highlights the urgent need for improved management strategies in pediatric BL patients in Pakistan to reduce infection-related complications and mortality rates, emphasizing the importance of context-specific approaches for infection prevention and management.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Factors associated with a prolonged hospital stay during induction chemotherapy in newly diagnosed high risk pediatric acute lymphoblastic leukemia
    Warrick, Kasper
    Althouse, Sandra K.
    Rahrig, April
    Rupenthal, Joy
    Batra, Sandeep
    LEUKEMIA RESEARCH, 2018, 71 : 36 - 42
  • [22] Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children's Oncology Group
    Shaikh, Furqan
    Cullen, John W.
    Olson, Thomas A.
    Pashankar, Farzana
    Malogolowkin, Marcio H.
    Amatruda, James F.
    Villaluna, Doojduen
    Krailo, Mark
    Billmire, Deborah F.
    Rescorla, Frederick J.
    Egler, Rachel A.
    Dicken, Bryan J.
    Ross, Jonathan H.
    Schlatter, Marc
    Rodriguez-Galindo, Carlos
    Frazier, A. Lindsay
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (11) : 1203 - 1210
  • [23] Clinical and demographic characteristics of Epstein-Barr virus-associated childhood Burkitt's lymphoma in Southeastern Brazil: epidemiological insights from an intermediate risk region
    Hassan, Rocio
    Klumb, Claudete Esteves
    Felisbino, Fabricio E.
    Guiretti, Deisy M.
    White, Lidia R.
    Stefanoff, Claudio Gustavo
    Barros, Mario Henrique M.
    Seuanez, Hector N.
    Zalcberg, Ilana R.
    HAEMATOLOGICA, 2008, 93 (05) : 780 - 783
  • [24] Improved outcomes in CNS-positive pediatric Burkitt lymphoma/leukemia using rituximab plus FAB group C1 chemotherapy without CNS radiation: a Children's Oncology Group report
    Frazer, J. K.
    Goldman, S. C.
    Smith, L.
    Harrison, L.
    Perkins, S. L.
    Cairo, M. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 : 3 - 3
  • [25] Reduced and compressed cisplatin-based chemotherapy in children and adolescents with intermediate-risk extracranial malignant germ cell tumors: A report from the Children's Oncology Group.
    Shaikh, Furcian
    Cullen, John W.
    Olson, Thomas Arthur
    Pashankar, Farzana
    Malogolowkin, Marcio H.
    Amatruda, James
    Villaluna, Doojduen
    Krailo, Mark D.
    Billmire, Deborah F.
    Rescorla, Frederick
    Egler, Rachel A.
    Dicken, Bryan J.
    Ross, Jonathan H.
    Schlatter, Marc
    Rodriguez-Galindo, Carlos
    Frazier, A. Lindsay
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] A Retrospective Study of Pediatric Patients With Low- or Intermediate-Risk Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation for the AML-05 Study Conducted by the Japanese Pediatric Leukemia/ Lymphoma Study Group
    Hashii, Yoshiko
    Kawaguchi, Koji
    Kurakami, Hiroyuki
    Umeda, Katsutsugu
    Hasegawa, Daiichiro
    Taki, Tomohiko
    Hyakuna, Nobuyuki
    Ishida, Hiroyuki
    Takahashi, Yoshiyuki
    Nagasawa, Masayuki
    Yabe, Hiromasa
    Yano, Michihiro
    Nakazawa, Yozo
    Fujisaki, Hiroyuki
    Matsumoto, Kimikazu
    Yanagimachi, Masakatsu
    Yoshida, Nao
    Kakuda, Harumi
    Satou, Atsushi
    Tabuchi, Ken
    Tomizawa, Daisuke
    Taga, Takashi
    Adachi, Souichi
    Koh, Katsuyoshi
    Kato, Koji
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (11): : 1102e1 - 1102e12
  • [27] Patterns of Relapse From a Phase III Study of Response-based Therapy for Intermediate-risk Hodgkin Lymphoma (AHOD0031): A Report From the Children's Oncology Group
    Dharmarajan, K. V.
    Friedman, D. L.
    Schwartz, C. L.
    Chen, L.
    FitzGerald, T.
    McCarten, K. M.
    Kessel, S. K.
    Iandoli, M.
    Constine, L. S.
    Wolden, S. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S5 - S6
  • [28] Adefovir dipivoxil to prevent exacerbation of lamivudine-resistant hepatitis B infection during chemotherapy for non-Hodgkin's lymphoma
    Enomoto, M
    Nishiguchi, S
    Seki, S
    Yamane, T
    Hino, M
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (08): : 1619 - 1620
  • [29] Mortality during treatment of patients with advanced Hodgkin's lymphoma undergoing dose escalated BEACOPP chemotherapy: An analysis of the German Hodgkin study group (GHSG).
    Fuchs, M
    Franklin, J
    Klimm, B
    Josting, A
    Pfistner, B
    Engert, A
    Diehl, V
    BLOOD, 2005, 106 (11) : 749A - 749A
  • [30] INTERLEUKIN 10 (IL10) PROMOTER POLYMORPHISMS ARE ASSOCIATED TO THE EPSTEIN-BARR VIRUS STATUS IN CHILDHOOD BURKITT'S LYMPHOMA: PATHOGENIC CLUES FROM AN INTERMEDIATE RISK REGION
    Minnicelli, C. E. M. Fonseca
    Barros, M. H. M.
    Zalcberg, I. Z.
    Hassan, R. H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 104 - 105